中东和非洲粘液补充剂市场，按来源（动物来源和非动物来源）、年龄组（老年人和成年人）、注射（单次注射、三次注射和五次注射）、分子量（中等分子量、低分子量和高分子量）、最终用户（医院、骨科诊所、门诊护理中心等）、分销渠道（直接招标和零售销售）划分 - 行业趋势和预测到 2029 年。
中东和非洲粘液补充市场分析和见解
预计中东和非洲粘液补充市场将在 2022 年至 2029 年的预测期内增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 6.2%。医疗保健领域粘液补充治疗技术的进步是推动预测期内中东和非洲粘液补充市场增长的另一个因素。
然而，治疗费用高昂，以及暂时注射、局部疼痛、肿胀、发热和红肿等副作用将限制市场的增长。主要市场参与者建立合作伙伴关系和收购等战略联盟，为中东和非洲粘弹性补充市场的增长提供了机会。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 |
|
定量单位 |
收入（百万美元） 销量（台数）、定价（美元） |
|
涵盖的领域 |
按来源（动物来源和非动物来源）、年龄组（老年人和成年人）、注射（单次注射、三次注射和五次注射）、分子量（中等分子量、低分子量和高分子量）、最终用户（医院、骨科诊所、门诊护理中心等）、分销渠道（直接招标和零售） |
|
覆盖国家 |
沙特阿拉伯、阿联酋、埃及、以色列、南非、科威特以及中东和非洲其他地区 |
|
涵盖的市场参与者 |
中东和非洲粘稠补充剂市场的一些主要参与者包括 Anika Therapeutics, Inc.、SEIKAGAKU CORPORATION、Bioventus、Fidia Farmaceutici SPA、Ferring BV、sanofi-aventis US LLC、Zimmer Biomet、OrthogenRx, Inc.（ AVNS)、APTISSEN、Johnson & Johnson Services, Inc.、LG Chem.、Viatris Inc.、 IBSA Institut Biochimique SA、Ortobrand International、TRB CHEMEDICA SA、Teva Pharmaceutical Industries Ltd.、Lifecore（Landec Corporation 的子公司）、VIRCHOW BIOTECH、Zuventus HealthCare Ltd.（Emcure Pharmaceuticals 的子公司）等。 |
市场定义
The development of the therapeutic paradigm viscosupplementation for long-lasting pain relief in human and animal joints with osteoarthritis or traumatic arthritis was based on the finding that in arthritic conditions, the average molecular weight and concentration of hyaluronan decreased. Consequently, the elastoviscous properties of the synovial fluid are substantially reduced. Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times greater concentration than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan used today for therapeutic purposes, the rheological properties (viscosity and elasticity) are low. Therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions. It has comparable rheological properties to the fluid found in young, healthy individuals. The clinical benefit of viscosupplementation is long-lasting pain relief in arthritic joints.
Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market.
Market Dynamics
Drivers
- Rising geriatric population
With this increasing age comes a reciprocal increase in the elderly patients admitted to the hospitals due to fatal traumatic injuries. The rising prevalence of knee osteoarthritis diseases leads to increasing demand for diagnosis and treatment. With the growing population, the pressure on the healthcare system is rising. The increasing need for the proper treatment proportionally surges the demand for care, services, and technologies for the prevention and treatment of knee osteoarthritis conditions such as sarcopenia, osteoporosis, osteopenia, and other complications. The elderly population is more prone to these conditions leading to fragile bones and joints. In such patients, viscosupplementation is used in the procedure to provide them with immediate and efficient benefits associated with their bodies.
With this increasing age and rising prevalence of osteoarthritis, the demand for early diagnosis of the diseases is also increasing. Therefore, the demand for viscosupplementation is rising for the treatment in the healthcare system across the globe.
- Increasing risk of osteoporosis and osteoarthritis
Osteoporosis is a disease of bone that progresses due to less bone mineral density and bone mass or due to some variation in the quality or structure of bone. Osteoporosis could increase the risk of fractures leading to broken bones due to decreased bone strength. It is more observed in women as compared to men. The post-menstrual women often get bone fractures due to osteoporosis as the disease is silent and typically shows no symptoms. Mostly elderly people are more prone to osteoporosis. Osteoarthritis is a joint disease or an inflammation of the joints and surrounding tissues. The mobility of a person is affected when such conditions occur.
The silent diseases such as osteoporosis and osteoarthritis show no symptoms and weaken the person's bone, leading to major fatalities such as spine malformation, fracture, sudden fall, or breakage of bone, among others. Thus, the increased risks of these conditions directly enhance the demand for viscosupplementation required to treat the malformations due to such conditions. Therefore, the increasing risk of osteoporosis and osteoarthritis is anticipated to drive the growth of the Middle East & Africa viscosupplementation market.
Restraint
- Lack of technical expertise
Finding, attracting, and hiring talent is also the first step in building a professional bench of engineers and technicians. Even in the best of circumstances, this procedure can be challenging. Manufacturing existing workforce is rapidly aging and retiring. In the medical industry, there is a scarcity of STEM (science, technology, engineering, and mathematics) skills. Although demand for skilled tradespeople (technicians) and undergraduate/post-graduate skills (engineers) remains strong in manufacturing, the number of people with the necessary skills is approaching a trickle. Only trained professionals should perform viscosupplementation, but this number is much less across the globe as these procedures are complex.
However, putting together a good additive manufacturing (AM) workforce entails more than just finding and recruiting qualified candidates. Employees must be qualified to remain current and maintain required skills as technology shift and grow. Even with their STEM-focused education, newly minted engineers would certainly need on-the-job training in AM techniques, which is one of the major challenges of recruiting and hiring them. Indeed, many undergraduate engineering programs provide little in the way of AM-specific education, and as a result, many graduates can lack the AM skills that employers seek.
Thus, the lack of technical expertise may act as a restraint for the market's growth.
Opportunity
- Safety and effectiveness of intra-articular hyaluronic acid (IAHA)
There are several types of hyaluronic acid injections, also called viscosupplementation, which are used for knee osteoarthritis. They are made from either rooster or chicken combs or are derived from bacteria and are injected directly into the joint. Intra-articular hyaluronic acid is a US Food and Drug Administration-approved treatment for knee osteoarthritis (OA). Intra-articular hyaluronic acid (IAHA) injection presents an alternative local treatment option providing symptomatic benefit without the systemic AEs associated with IA corticosteroids. Numerous RCTs and meta-analyses have sought to assess the efficacy and safety of IAHA, with mixed results and conclusions. IAHA is demonstrated to have a positive effect on pain and joint function. There is also mounting data showing that multiple courses of IAHA can impact long-term outcomes, including a reduction in concomitant analgesia use and a delay in the need for total knee replacement surgery.
Challenge
- Stringent government policies for THE USE OF viscosupplementation
The commercialization of viscosupplementation across the globe by various key market players is facilitated by compliance with the regulatory frameworks established by many countries across the globe. The pre-market approval of various medical devices varies from one country to another. The U.S. Food, Drug, and Cosmetic Act ("FD&C Act") classify medical devices in the U.S. The European Union (EU) regulates medical devices in Europe. However, the rapid development of privacy policies and regulations are being made in the Asia-Pacific and EMEA, including India, Russia, China, South Korea, Singapore, Hong Kong, and Australia.
The viscosupplementation is regulated by a structure of laws, rules, and regulations that are extensive and complex to safeguard them from use in any potential harmful treatment.
The viscosupplementation act as a replacement for the damaged, injured, or infected body parts in cases of osteoarthritis conditions or sports accidents among patients, along with maintaining the patient's demand for good body movement. However, any misguidance will affect the patient's safety and body structure.
Therefore, the stringent rules & regulations for the use of viscosupplementation may act as a challenge to the growth of the market.
Post COVID-19 Impact on the Middle East & Africa Viscosupplementation Market
COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to impact the Middle East & Africa viscosupplementation market greatly.
Middle East & Africa Viscosupplementation Market Scope and Market Size
Middle East & Africa viscosupplementation market is segmented on the basis of source, age group, molecular weight, injection, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the Difference in your target markets.
BY SOURCE
- ANIMAL ORIGIN
- NON-ANIMAL ORIGIN
On the basis of source, the viscosupplementation market is segmented into the animal origin and non-animal origin.
BY MOLECULAR WEIGHT
- HIGH MOLECULAR WEIGHT
- LOW MOLECULAR WEIGHT
- INTERMEDIATE MOLECULAR WEIGHT
On the basis of molecular weight, the viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight.
BY INJECTION
- SINGLE INJECTION
- THREE INJECTION
- FIVE INJECTION
On the basis of injection, the viscosupplementation market is segmented into single injection, three injections, and five injections.
BY AGE GROUP
- ADULTS
- GERIATRICS
On the basis of age group, the viscosupplementation market is segmented into geriatric and adults.
END-USER
- HOSPITALS
- ORTHOPEDIC CLINIC
- HOME HEALTHCARE
- OTHERS
On the basis of end-user, the viscosupplementation market is segmented into hospital, orthopedic clinics, ambulatory care centers, and others.
BY DISTRIBUTION CHANNEL
- DIRECT TENDER
- RETAIL SALES
On the basis of distribution channel, the viscosupplementation market is segmented into direct tender and retail sales.
Viscosupplementation Market Country Level Analysis
The viscosupplementation market is analyzed, and market size information is provided by source, age group, molecular weight, injection, end user, and distribution channel.
The countries covered in the Middle East & Africa viscosupplementation market report are the Saudi Arabia, U.A.E, Egypt, Israel, South Africa, Kuwait, and rest of the Middle East and Africa.
In 2022, South Africa is dominating due to the rise in the incidence of obesity and osteoarthritis. South Africa is expected to grow due to technological advancements in drug treatments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.
Middle East & Africa viscosupplementation market also provides you with a detailed market analysis for every country growth in the healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, the impact of regulatory scenarios, and trending parameters regarding the Middle East & Africa viscosupplementation market.
Competitive Landscape and Middle East & Africa Viscosupplementation Market Share Analysis
Middle East & Africa viscosupplementation market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to viscosupplementation treatments.
The major companies which are dealing in the viscosupplementation market are Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici S.P.A, Ferring B.V, sanofi-aventis U.S. LLC, Zimmer Biomet, OrthogenRx, Inc. (a subsidiary of AVNS), APTISSEN, Johnson & Johnson Services, Inc., LG Chem., Viatris Inc., IBSA Institut Biochimique SA, Ortobrand International, TRB CHEMEDICA SA, Teva Pharmaceutical Industries Ltd., Lifecore (a subsidiary of Landec Corporation), VIRCHOW BIOTECH, Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals), among others
Strategic alliances like mergers, acquisitions, and agreements by the key market players are further expected to accelerate the growth of viscosupplementation treatments.
For instance,
- In May, 2022, Fidia Farmaceutici S.p.A. harnesses the regenerative power of hyaluronic acid with its innovative portfolio launched in Spain
Fidia Farmaceutici S.p.A. presented its Aesthetic Care portfolio with a scientific symposium on its innovative ACP (Auto-Crosslinked Polymer) technology at the 20th Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC) in Monte Carlo. The company has launched its complete Hyal System and Hy-Tissue portfolio in Spain. This has helped the company to showcase its research for hyaluronic acid
- In June 2022, Johnson & Johnson announced new data from Phase 3 studies demonstrating patients treated with medicine achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis, a dactylitis,b spinal pain, and disease severityc endpoints – irrespective of baseline characteristics. This has helped the company to showcase its progress
- 2021 年 11 月，LG 化学启动了新一代骨关节炎治疗药物的临床开发。LG 化学宣布，基于骨关节炎治疗新药候选药物 LG00034053 的临床前阳性结果，该公司已获得韩国食品药品安全部 1b/2 期临床试验的批准。LG 化学计划通过设计连接 1 期和 2 期的临床试验来加速新药的开发。
这有助于该公司开发治疗骨关节炎的新药
- 2020 年 11 月，Viatris Inc. 成功整合了 Mylan NV 和辉瑞的 Upjohn 业务。通过整合这两家互补的传统公司，Viatris 拥有科学、制造和分销专业知识，以及经过验证的监管、医疗和中东及非洲商业能力，可为 165 多个国家和地区的患者提供高质量的药品。这有助于公司扩大业务
合作、产品发布、业务扩展、奖励和认可、合资企业以及市场参与者的其他策略正在增强公司在中东和非洲粘液补充市场的影响力，这也有利于该组织的利润增长。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、MEA 与区域以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
7 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET
8 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: REGULATIONS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING GERIATRIC POPULATION
9.1.2 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS
9.1.3 TECHNOLOGICAL ADVANCEMENT IN VISCOSUPPLEMENTATION
9.1.4 LOW PRODUCTION COST OF VISCOSUPPLEMENTATION PRODUCTS
9.2 RESTRAINTS
9.2.1 LACK OF TECHNICAL EXPERTISE
9.2.2 PRODUCT RECALL PROCEDURES
9.2.3 LIMITED APPLICATIONS OF VISCOSUPPLEMENTATION
9.3 OPPORTUNITIES
9.3.1 SAFETY AND EFFECTIVENESS OF INTRA-ARTICULAR HYALURONIC ACID (IAHA)
9.3.2 RISING HEALTHCARE INFRASTRUCTURE
9.3.3 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES
9.3.4 INCREASING NUMBER OF JOINT REPLACEMENTS AND SPORTS ACCIDENT
9.4 CHALLENGES
9.4.1 STRINGENT GOVERNMENT POLICIES FOR THE USE OF VISCOSUPPLEMENTATION
9.4.2 SIDE-EFFECTS OF VISCOSUPPLEMENTATION
10 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NON-ANIMAL ORIGIN
10.2.1 ORTHOVISC
10.2.2 EUFLEXXA
10.2.3 MONOVISC
10.2.4 DUROLANE
10.2.5 GEL-ONE
10.2.6 SUPARTZ
10.2.7 GELSYN-3
10.2.8 CINGAL
10.2.9 SULPLASYN
10.2.10 VISCOSEAL
10.2.11 OSTEONIL
10.2.12 OTHERS
10.3 ANIMAL ORIGIN
10.3.1 HYLAN G-F 20
10.3.2 SYNVIC ONE
10.3.3 SYNVIC
10.3.4 OTHERS
10.3.5 HYALURONANS
10.3.6 HYALGAN
10.3.7 OTHERS
11 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT
11.1 OVERVIEW
11.2 INTERMEDIATE MOLECULAR WEIGHT
11.2.1 ORTHOVISC
11.2.2 EUFLEXXA
11.2.3 MONOVISC
11.2.4 DUROLANE
11.2.5 VISCOSEAL
11.2.6 OSTEONIL
11.2.7 OTHERS
11.3 LOW MOLECULAR WEIGHT
11.3.1 HYLAGAN
11.3.2 SUPARTZ
11.3.3 GELSYN-3
11.3.4 CINGAL
11.3.5 SULPLASYN
11.3.6 OTHERS
11.4 HIGH MOLECULAR WEIGHT
11.4.1 SYNVIC ONE
11.4.2 SYNVIC
11.4.3 OTHERS
12 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY INJECTION
12.1 OVERVIEW
12.2 SINGLE INJECTION
12.3 THREE INJECTION
12.4 FIVE INJECTION
13 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULTS
13.3 GERIATRIC
14 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 ORTHOPEDIC CLINICS
14.4 AMBULATORY CARE CENTERS
14.5 OTHERS
15 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.3 DIRECT TENDER
16 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 EGYPT
16.1.3 SAUDI ARABIA
16.1.4 U.A.E
16.1.5 ISRAEL
16.1.6 KUWAIT
16.1.7 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 JOHNSON & JOHNSON SERVICES, INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 BIOVENTUS
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 FERRING B.V.
19.3.1 COMPANY SNAPSHOT
19.3.2 COMPANY SHARE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 SANOFI-AVENTIS U.S. LLC
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 ZIMMER BIOMET
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 SEIKAGAKU CORPORATION
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ANIKA THERAPEUTICS, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 FIDIA FARMACEUTICI S.P.A
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 APTISSEN
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 IBSA INSTITUT BIOCHIMIQUE SA
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 LG CHEM.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 LIFECORE (A SUBSIDIARY OF LANDEC CORPORATION)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 ORTHOGENRX, INC. (A SUBSIDIARY OF AVNS)
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 ORTOBRAND INTERNATIONAL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 TEVA PHARMACEUTICAL INDUSTRIES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 TRB CHEMEDICA SA
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENTS
19.17 VIATRIS INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 VIRCHOW BIOTECH
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 ZUVENTUS HEALTHCARE LTD. (A SUBSIDIARY OF EMCURE PHARMACEUTICALS)
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA NON-ANIMAL IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 5 MIDDLE EAST & AFRICA ANIMAL IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 9 MIDDLE EAST & AFRICA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 11 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA SINGLE INJECTION IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA THREE INJECTION IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA FIVE INJECTION IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA ADULT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA GERIATRIC IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA HOSPITALS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA ORTHOPEADIC CLINICS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA AMBULATORY CARE CENTERS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA OTHERS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA RETAIL SALES IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA DIRECT TENDER IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 37 MIDDLE EAST AND AFRICA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 40 MIDDLE EAST AND AFRICA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 42 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 53 SOUTH AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 54 SOUTH AFRICA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 57 SOUTH AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 58 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 59 SOUTH AFRICA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 62 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 63 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 64 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 EGYPT VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 67 EGYPT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 68 EGYPT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 69 EGYPT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 70 EGYPT ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 EGYPT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 72 EGYPT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 73 EGYPT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 74 EGYPT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 75 EGYPT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 76 EGYPT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 77 EGYPT VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 78 EGYPT INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 79 EGYPT LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 80 EGYPT HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 81 EGYPT VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 82 EGYPT VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 83 EGYPT VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 EGYPT VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 86 SAUDI ARABIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 87 SAUDI ARABIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 88 SAUDI ARABIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 89 SAUDI ARABIA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 SAUDI ARABIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 91 SAUDI ARABIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 92 SAUDI ARABIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 93 SAUDI ARABIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 94 SAUDI ARABIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 95 SAUDI ARABIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 96 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 97 SAUDI ARABIA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 98 SAUDI ARABIA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 99 SAUDI ARABIA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 100 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 101 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 102 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 103 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 104 U.A.E VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 105 U.A.E NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 106 U.A.E NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 107 U.A.E NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 108 U.A.E ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 U.A.E HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 110 U.A.E HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 111 U.A.E HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 112 U.A.E HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 113 U.A.E HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 114 U.A.E HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 115 U.A.E VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 116 U.A.E INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 117 U.A.E LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 118 U.A.E HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 119 U.A.E VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 120 U.A.E VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 121 U.A.E VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 U.A.E VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 ISRAEL VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 124 ISRAEL NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 125 ISRAEL NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 126 ISRAEL NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 127 ISRAEL ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 ISRAEL HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 129 ISRAEL HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 130 ISRAEL HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 131 ISRAEL VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 132 ISRAEL INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 133 ISRAEL LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 134 ISRAEL HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 135 ISRAEL VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 136 ISRAEL VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 137 ISRAEL VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 138 ISRAEL VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 139 KUWAIT VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 140 KUWAIT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 141 KUWAIT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 142 KUWAIT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 143 KUWAIT ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 KUWAIT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 145 KUWAIT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 146 KUWAIT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 147 KUWAIT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 148 KUWAIT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 149 KUWAIT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 150 KUWAIT VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 151 KUWAIT INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 152 KUWAIT LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 153 KUWAIT HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 154 KUWAIT VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 155 KUWAIT VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 156 KUWAIT VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 KUWAIT VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 158 REST OF MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 THE INCREASING DEMAND FOR NON-SURGICAL TREATMENTS FOR OSTEOARTHRITIS AND ADVANCEMENTS IN THE DEVELOPMENT OF HYALURONIC ACID-BASED THERAPIES IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 NON-ANIMAL ORIGIN IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET
FIGURE 15 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE, 2021
FIGURE 16 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE, 2022-2029 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE, CAGR (2022-2029)
FIGURE 18 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, 2021
FIGURE 20 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, 2022-2029 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, CAGR (2022-2029)
FIGURE 22 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY INJECTION, 2021
FIGURE 24 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY INJECTION, 2022-2029 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY INJECTION, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY INJECTION, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, 2021
FIGURE 28 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY END USER, 2021
FIGURE 32 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY END USER, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 36 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: SNAPSHOT (2021)
FIGURE 40 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: BY COUNTRY (2021)
FIGURE 41 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE (2022-2029)
FIGURE 44 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
